

Technical Information Report

AAMI TIR43: 2021

Ultrapure dialysis fluid for
hemodialysis and related
therapies

Ultrapure dialysis fluid for hemodialysis and related therapies

Approved 26 February 2021 by
AAMI

Abstract: Addresses preparation and use of ultrapure fluids to perform hemodialysis. Fluids include water and dialysis fluid. Includes the definition of ultrapure fluids, the rationale for their use, and the means by which they can be prepared. Does not cover peritoneal dialysis fluids.

Keywords: fluid, preparation, use, water

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N Glebe Rd., Suite 300, Arlington, VA 22203-1633.

Published by

Association for the Advancement of Medical Instrumentation
901 N Glebe Rd., Suite 300
Arlington, VA 22203-1633
www.aami.org

© 2021 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at www.aami.org or contact AAMI at 901 N Glebe Rd., Suite 300, Arlington, VA 22203-1633. Phone: +1-703-525-4890; Fax: +1-703-525-1067.

Printed in the United States of America

ISBN 978-1-57020-815-7

Contents

Page

Committee representation	iv
Foreword	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Rationale for the use of ultrapure dialysis fluid	2
5 Strategies to achieve ultrapure dialysis fluid	6
6 Strategies for reducing biofilm formation	21
7 Demonstrating compliance with recommendations for the microbial quality of dialysis fluid	23
Bibliography	29

Tables

Table 1—System processes and common technologies used in the production and distribution of dialysis water, fluid concentrates, and dialysis fluids including standard dialysis fluid, ultrapure dialysis fluid and substitution fluid	7
Table 2—Microbiological techniques for monitoring water and dialysis fluid in ISO water and dialysis fluid standards	24

Figures

Figure 1—Common system configurations for dialysis water preparation and distribution	7
Figure 2—Common system configurations for bicarbonate and acid concentrate preparation and distribution	9
Figure 3—Example of a validation process for a fluid preparation and distribution system	11

Committee representation

Association for the Advancement of Medical Instrumentation

Renal Disease and Detoxification Committee

This Technical Information Report was developed by the AAMI Renal Disease and Detoxification Committee. Committee approval of the Technical Information Report does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Renal Disease and Detoxification Committee** had the following members:

Cochairs: Jo-Ann Maltais, PhD
Denny Treu

Members: Tom Allocco, US Renal Care
Matthew J. Arduino, DrPH, U.S. Centers for Disease Control and Prevention
Christian Bluechel, Singapore
Aaron Brown, Baxter Healthcare
Karla Byrne, Rockwell Medical
Christopher A. Cloonan, CBNT, CDWS, UVA Augusta Dialysis
Danilo B. Concepcion, CBNT, CCHT-A, FNKF, St. Joseph Health System
Deborah Cote, MSN, RN, CNN, National Renal Administrators Association
Conor Curtin, Boston, MA
Jack Dillon, Medical Solutions International
Pamela Elliott, MHA, BSN, McLeod Regional Medical Center
Bruce Fife, Reprocessing Products Corporation
Gema Gonzalez, U.S. Food and Drug Administration (CDRH/ODE)
Kalub Hahne, PhD, Cook Research Inc.
Joe Haney, AmeriWater
Peter F. Haywood, AWAK Technologies
Steven Hoffman, CBET, Children's Hospital of Pittsburgh
Robert Hootkins, MD, PhD, FASN, LSCM Consulting
Byron Jacobs, CBET, GE Healthcare
Richard J. Kaestner, Jr., Absolute Water Technologies
Ted A. Kasperek, Davita
Kristi Keller, Iredell Health System
Kendall Larson, Marquest Purification
Robert Levin, Renal Research Institute
Jo-Ann Maltais, PhD, Maltais Consulting
Duane Martz, MAEE/MBA, B Braun of America
John Maurino, MS, MBA, Calgon Carbon Corporation
Klemens Meier, MD, Tufts Medical Center
Emily Michalak, AAS, BS, Satellite Healthcare
Paul F. Miller, MD, Dialysis Clinic/Kidney Consultants of Louisiana
Anilkumar Natarajan, Sidra Medical & Research Center, Qatar
Glenda Payne, RN, MS, CNN, American Nephrology Nurses Association
Toshiya Roberts, American Renal Associates
Joseph Sala, BSc Ed, Mount Sinai Medical Center
David Schmidt, Mayo Clinic
Amanda Tilles, Design Science Consulting
Denny Treu, BSME, Fresenius Medical Care - NxStage
Ashish Upadhyay, Boston University – School of Medicine
Richard A. Ward, PhD, Nelson, New Zealand

Alternates: Emily Borst, Design Science Consulting
Jenalle Brewer, Calgon Carbon Corporation
Logan Cabral, AmeriWater
Martin Crnkovich BSEE, Fresenius Medical Care

Anthony Messana, National Renal Administrators Association
Mark Pasmore, PhD, Baxter Healthcare
Martin Roberts, PhD, AWAK Technologies
Vern S. Taaffe, Reprocessing Products Corporation
Ronald Trammell, American Renal Associates
Michael Verguldi, Mar Cor Purification
Richard Williams, U.S. Food and Drug Administration/CDRH

NOTE Participation by federal agency representatives in the development of this Technical Information Report does not constitute endorsement by the federal government or any of its agencies.

Foreword

This technical information report was developed by the AAMI Renal Disease and Detoxification Committee. The objective is to provide technical information that will assist medical device manufacturers in determining acceptable levels of particulate on medical device products used to deliver or implant into the vasculature, or both.

The following verbal forms are used within AAMI documents to distinguish requirements from other types of provisions in the document:

- “shall” and “shall not” are used to express requirements;
- “should” and “should not” are used to express recommendations;
- “may” and “may not” are used to express permission;
- “can” and “cannot” are used as statements of possibility or capability;
- “might” and “might not” are used to express possibility;
- “must” is used for external constraints or obligations defined outside the document, “must” is not an alternative for “shall.”

Suggestions for improving this recommended practice are invited. Comments and suggested revisions should be sent to Standards, AAMI, 901 N Glebe Road, Suite 300, Arlington, VA 22203 or standards@aami.org.

NOTE This foreword does not contain provisions of the AAMI TIR43, *Ultra-pure dialysis fluid for hemodialysis and related therapies* (AAMI TIR43:2021), but it does provide important information about the development and intended use of the document.

Introduction

Hemodialysis patients are directly exposed to large volumes of dialysis fluid, with the dialyser membrane being the only barrier against the transfer of potentially hazardous contaminants from the dialysis fluid to the patient. It has long been known that there could be contaminants in dialysis fluid that are hazardous to patients. To minimize this hazard, ANSI/AAMI/ISO 23500-5:2019, *Guidance for the preparation and quality management of fluids for haemodialysis and related therapies — Part 5: Quality of dialysis fluid for hemodialysis and related therapies* [1], establishes quality requirements for dialysis fluid used in hemodialysis and related therapies. These quality requirements define two classes of dialysis fluid: standard dialysis fluid and ultrapure dialysis fluid. The maximum allowable levels of chemical contaminants are the same for both standard dialysis fluid and ultrapure dialysis fluid; however, they differ in the maximum allowable levels of microbial contaminants. According to ANSI/AAMI/ISO 23500-1:2019, *Guidance for the preparation and quality management of fluids for hemodialysis and related therapies — Part 1: General requirements* [2], dialysis fluid complying with the requirements for standard dialysis fluid is the minimum quality acceptable for routine hemodialysis. However, it recommends that ultrapure dialysis fluid be used, even for routine hemodialysis. The recommendation is based on clinical and experimental observations that improving the microbiological purity of dialysis fluid is associated with reduced levels of inflammation and a reduction in morbidities associated with inflammation. These apparent advantages of ultrapure dialysis fluid might not be widely appreciated and implementing the routine use of ultrapure dialysis fluid could require changes in dialysis unit practices. For these reasons, this Technical Information Report was developed to provide background information on ultrapure dialysis fluid and to review strategies that could be helpful in implementing its routine use.

This Technical Information Report is directed at healthcare professionals involved in the management of dialysis facilities (dialysis units) and the routine care of patients treated in dialysis facilities, because they are responsible for the final preparation of dialysis fluid.

Ultrapure dialysis fluid for hemodialysis and related therapies

1 Scope

This Technical Information Report (TIR) addresses the preparation of ultrapure dialysis fluid from water and concentrates and its use in performing hemodialysis and related therapies in dialysis facilities (dialysis units).

1.1 Inclusions

The Technical Information Report includes the definition of ultrapure dialysis fluid, the rationale for its use, and some means by which it can be prepared and other considerations. Manufacturer and user roles and responsibilities are presented.

1.2 Exclusions

This Technical Information Report does not cover peritoneal dialysis fluids or prepackaged dialysis fluids, such as those used in continuous renal replacement therapies (CRRT). This TIR does not apply to home dialysis systems.

NOTE While this TIR is primarily directed at the preparation of ultrapure dialysis fluid in dialysis facilities, aspects of it might also apply to home dialysis with standard dialysis machines.

2 Normative references

There are no normative references in this document.

3 Terms and definitions

Ultrapure dialysis fluid is defined by the level of microbiological contamination. While chemical contaminants in the dialysis fluid can harm patients, there is as yet no evidence to show that reducing chemical contaminant levels below those specified in ANSI/AAMI/ISO 23500-3, *Guidance for the preparation and quality management of fluids for haemodialysis and related therapies - Part 3: Water for haemodialysis and related therapies* [3], improves patient outcomes. Therefore, this clause is limited to defining different levels of dialysis fluid quality based on microbiological contaminants.

3.1

dialysis fluid

dialysate

dialysis solution

aqueous fluid containing electrolytes and, usually, buffer and glucose, which is intended to exchange with blood contaminants during hemodialysis and hemodiafiltration.

Note 1 to entry: The term “dialysis fluid” is used throughout this document to mean the fluid made from dialysis water and concentrates that is delivered to the dialyser by the dialysis fluid delivery system. Such phrases as “dialysate” or “dialysis solution” are used in place of “dialysis fluid” in some countries; however, that usage is discouraged to avoid confusion.

Note 2 to entry: ANSI/AAMI/ISO 23500-5 [1] defines three levels of dialysis fluid: standard dialysis fluid, ultrapure dialysis fluid, and online-prepared substitution fluid used for haemodiafiltration.

Note 3 to entry: The dialysis fluid entering the dialyser is referred to as “fresh dialysis fluid”, while the fluid leaving the dialyser is referred to as “spent dialysis fluid.”